| Year |
Citation |
Score |
| 2008 |
Blackler AR, Speers AE, Wu CC. Chromatographic benefits of elevated temperature for the proteomic analysis of membrane proteins. Proteomics. 8: 3956-64. PMID 18780350 DOI: 10.1002/Pmic.200800210 |
0.625 |
|
| 2008 |
Blackler AR, Speers AE, Ladinsky MS, Wu CC. A shotgun proteomic method for the identification of membrane-embedded proteins and peptides. Journal of Proteome Research. 7: 3028-34. PMID 18537282 DOI: 10.1021/Pr700795F |
0.605 |
|
| 2008 |
Blackler AR, Wu CC. Proteomic characterization of membrane protein topology. Methods in Molecular Biology (Clifton, N.J.). 432: 185-97. PMID 18370019 DOI: 10.1007/978-1-59745-028-7_13 |
0.619 |
|
| 2008 |
Finney GL, Blackler AR, Hoopmann MR, Canterbury JD, Wu CC, MacCoss MJ. Label-free comparative analysis of proteomics mixtures using chromatographic alignment of high-resolution μLC-MS data Analytical Chemistry. 80: 961-971. PMID 18189369 DOI: 10.1021/Ac701649E |
0.499 |
|
| 2007 |
Speers AE, Blackler AR, Wu CC. Shotgun analysis of integral membrane proteins facilitated by elevated temperature. Analytical Chemistry. 79: 4613-20. PMID 17500534 DOI: 10.1021/Ac0700225 |
0.629 |
|
| 2006 |
Blackler AR, Klammer AA, MacCoss MJ, Wu CC. Quantitative comparison of proteomic data quality between a 2D and 3D quadrupole ion trap. Analytical Chemistry. 78: 1337-44. PMID 16478131 DOI: 10.1021/Ac051486A |
0.415 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2015 |
Cecchi F, Blackler A, Jordan H, Stocum M, Darfler M, Hembrough T, Burrow J. Clinical Survey of actionable proteins in multiple indications using multiplex mass spectrometry Annals of Oncology. 26: ii21. DOI: 10.1093/Annonc/Mdv092.2 |
0.279 |
|
| 2013 |
Blackler AR, Morgan NY, Gao B, Olano LR, Armani MD, Romantseva E, Kakareka JW, Bonner RF, Mukherjee S, Xiao B, Tran K, Pohida TJ, Emmert-Buck MR, Tangrea MA, Markey SP. Proteomic analysis of nuclei dissected from fixed rat brain tissue using expression microdissection. Analytical Chemistry. 85: 7139-45. PMID 23799655 DOI: 10.1021/Ac400691K |
0.275 |
|
| 2016 |
Sellappan S, Blackler A, Liao WL, O'Day E, Xu P, Thyparambil S, Cecchi F, Hembrough T, Catenacci DV. Therapeutically Induced Changes in HER2, HER3, and EGFR Protein Expression for Treatment Guidance. Journal of the National Comprehensive Cancer Network : Jnccn. 14: 503-7. PMID 27160229 DOI: 10.6004/Jnccn.2016.0059 |
0.273 |
|
| 2012 |
Zhu L, Du Q, Blackler AR, Tangrea MA, Emmert-Buck MR. In situ proteomic analysis of histological sections Current Proteomics. 9: 71-79. DOI: 10.2174/157016412800786220 |
0.267 |
|
| 2015 |
Ock C, An E, Oh D, Kim T, Lee K, Han S, Im S, Kim T, Liao W, Cecchi F, Blackler A, Thyparambil SP, Hoos WA, Kim WH, Burrows J, et al. Quantitative measurement of HER2 levels by multiplexed mass spectrometry to predict survival in gastric cancer patients treated with trastuzumab. Journal of Clinical Oncology. 33: 4050-4050. DOI: 10.1200/Jco.2015.33.15_Suppl.4050 |
0.244 |
|
| 2019 |
Ducret A, James I, Wilson S, Feilke M, Tebbe A, Dybowski N, Elschenbroich S, Klammer M, Blackler A, Liao WL, Tian Y, Friess T, Bossenmaier B, Dietmann G, Schaab C, et al. Translation and evaluation of a pre-clinical 5-protein response prediction signature in a breast cancer phase Ib clinical trial. Plos One. 14: e0213892. PMID 30897176 DOI: 10.1371/journal.pone.0213892 |
0.212 |
|
| 2015 |
Hembrough TA, Cecchi F, Blackler A, Thyparambil SP, Burrows J, O'Shaughnessy J. Proteomic analysis of primary and metastatic breast cancers and expression of the folate receptor as a potential drug target. Journal of Clinical Oncology. 33: 1045-1045. DOI: 10.1200/Jco.2015.33.15_Suppl.1045 |
0.194 |
|
| 2016 |
Abdulrahman A, An E, Cecchi F, Blackler A, Sellappan S, Smolkin M, Hembrough T, Monga M. Quantitative mass spectrometry-based proteomics identifies FRalpha and GARFT as predictive biomarkers in tissues of non-squamous NSCLC patients treated with pemetrexed Journal of Thoracic Oncology. 11: S18-S19. DOI: 10.1016/J.Jtho.2015.12.032 |
0.168 |
|
| 2016 |
Rosenberg AZ, Armani MD, Fetsch PA, Xi L, Pham TT, Raffeld M, Chen Y, O'Flaherty N, Stussman R, Blackler AR, Du Q, Hanson JC, Roth MJ, Filie AC, Roh MH, et al. High-Throughput Microdissection for Next-Generation Sequencing. Plos One. 11: e0151775. PMID 26999048 DOI: 10.1371/Journal.Pone.0151775 |
0.167 |
|
| 2016 |
Segall D, Xenakis J, Hertz D, Sellappan S, Blackler A, Levine J, Rabizadeh S, Hembrough TA. Economic impact and outcome benefits of integrating quantitative proteomics analysis to guide treatment strategies for metastatic breast cancer patients. Journal of Clinical Oncology. 34: e18242-e18242. DOI: 10.1200/jco.2016.34.15_suppl.e18242 |
0.1 |
|
| 2015 |
Catenacci DV, Liao WL, Zhao L, Whitcomb E, Henderson L, O'Day E, Xu P, Thyparambil S, Krizman D, Bengali K, Uzzell J, Darfler M, Cecchi F, Blackler A, Bang YJ, et al. Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH. Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. PMID 26581548 DOI: 10.1007/S10120-015-0566-0 |
0.095 |
|
| 2018 |
Buttigliero C, Shepherd FA, Barlesi F, Schwartz B, Orlov S, Favaretto AG, Santoro A, Hirsh V, Ramlau R, Blackler AR, Roder J, Spigel D, Novello S, Akerley W, Scagliotti GV. Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. The Oncologist. PMID 30139835 DOI: 10.1634/theoncologist.2018-0089 |
0.043 |
|
| 2010 |
Fox MA, French HT, LaPorte JL, Blackler AR, Murphy DL. The serotonin 5-HT(2A) receptor agonist TCB-2: a behavioral and neurophysiological analysis. Psychopharmacology. 212: 13-23. PMID 19823806 DOI: 10.1007/S00213-009-1694-1 |
0.03 |
|
| Hide low-probability matches. |